Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

Effect of Fingolimod on Neurodegeneration

NCT02575365 ·Status: TERMINATED ·Phase: PHASE4

Administration of Fingolimod in Greek Patients With Multiple Sclerosis.

NCT06949956 ·Status: NOT_YET_RECRUITING

Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis

NCT02021162 ·Status: COMPLETED

Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program

NCT01281657 ·Status: COMPLETED

Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS

NCT01592097 ·Status: COMPLETED

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

NCT04480853 ·Status: RECRUITING ·Phase: PHASE4

Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis

NCT03345940 ·Status: TERMINATED ·Phase: PHASE4

Safety and Efficacy of Fingolimod in MS Patients in China

NCT01941004 ·Status: WITHDRAWN ·Phase: PHASE3

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

NCT01442194 ·Status: COMPLETED

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Impact of Fingolimod Adherence on Outcomes

NCT05141669 ·Status: COMPLETED

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT00662649 ·Status: COMPLETED ·Phase: PHASE3

ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon

NCT01621269 ·Status: WITHDRAWN ·Phase: PHASE4

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

NCT01623596 ·Status: COMPLETED ·Phase: PHASE4

Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya

NCT02325440 ·Status: UNKNOWN ·Phase: PHASE4

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

NCT01499667 ·Status: TERMINATED ·Phase: PHASE3

Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate

NCT02307877 ·Status: COMPLETED

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT00355134 ·Status: COMPLETED ·Phase: PHASE3

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT01497262 ·Status: COMPLETED ·Phase: PHASE3

Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis

NCT01981161 ·Status: COMPLETED

Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

NCT02228213 ·Status: COMPLETED ·Phase: PHASE2

Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients

NCT02939079 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

NCT00340834 ·Status: COMPLETED ·Phase: PHASE3

Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran

NCT04928313 ·Status: COMPLETED

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT01310166 ·Status: COMPLETED ·Phase: PHASE4